Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics, Inc. (NASDAQ: PTCT) is a global biopharmaceutical company focused on clinically differentiated medicines for children and adults living with rare disorders. The PTCT news feed on Stock Titan aggregates company announcements, financial updates and regulatory milestones that PTC discloses through press releases and SEC filings.
Investors following PTCT news can see updates on the commercial performance and global rollout of products such as Sephience (sepiapterin) for phenylketonuria (PKU), as well as revenue contributions from the company’s Duchenne muscular dystrophy franchise, which includes Translarna (ataluren) and Emflaza (deflazacort). News items also cover royalty revenue from Evrysdi (risdiplam) and changes in royalty arrangements, such as the sale of certain Evrysdi royalty rights to Royalty Pharma.
PTC Therapeutics regularly reports quarterly and annual financial results, including total revenue, product revenue, royalty and collaboration revenue, and details on GAAP and non-GAAP R&D and SG&A expenses. Corporate updates often highlight pipeline and regulatory developments, including FDA meetings for programs like votoplam in Huntington’s disease and vatiquinone in Friedreich’s ataxia, as well as ongoing review of the Translarna NDA.
The company also issues news about regulatory approvals and launches in different regions, such as Sephience approvals in the EU, US and Japan, and about R&D-focused events and investor conference presentations. In addition, PTC discloses equity inducement grants under Nasdaq Listing Rule 5635(c)(4), illustrating its use of stock options and restricted stock units as part of employee compensation.
By monitoring the PTCT news page, readers can track how product launches, regulatory decisions, collaborations, royalty transactions and capital markets activities shape the company’s progress in the rare disease biopharmaceutical sector.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webcast conference call on October 29, 2020, at 4:30 p.m. (ET), to report third quarter 2020 financial results and update its business outlook. Investors can access the call by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) with the passcode 7096445. A live webcast will also be available on the company’s website and a replay will be archived for 30 days. PTC focuses on developing medicines for rare disorders and aims to provide access to innovative treatments.
On September 28, 2020, PTC Therapeutics announced positive two-year data from the FIREFISH study on Evrysdi™ (risdiplam) for treating spinal muscular atrophy (SMA). The study indicated that 88% of infants were alive without permanent ventilation after two years. Significant motor milestones were achieved, including increased independent sitting and head control. The treatment's safety profile remained consistent, with no new safety signals. Evrysdi™ was recently approved and shows a strong commercial launch, highlighting its importance amid the ongoing pandemic.
PTC Therapeutics announced on September 21, 2020, the approval of stock options for 75,670 shares and 12,845 restricted stock units (RSUs) to 22 new employees, as part of their employment compensation. These inducement grants comply with NASDAQ's listing rules and aim to attract new talent. The options have an exercise price of $45.46 per share, with a 10-year term and a four-year vesting schedule. The RSUs will also vest over four years. PTC focuses on developing innovative treatments for rare disorders, driving their investment in a strong pipeline of medicines.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will present a company overview on October 1, 2020, at the Jefferies Virtual Gene Therapy/Editing Summit at 9:00 a.m. ET. The presentation will be live-streamed on their website and available for 30 days afterward. PTC Therapeutics focuses on developing medicines for rare disorders, aiming to provide access to innovative treatments for patients with unmet needs. For optimal viewing, it's recommended to connect a few minutes before the start of the webcast.
PTC Therapeutics (NASDAQ: PTCT) announced the winners of its sixth annual STRIVE Awards, recognizing initiatives aimed at supporting the Duchenne muscular dystrophy community. Awarded projects include an online platform in Argentina, events in Hungary connecting families with healthcare professionals, a support program in Russia, and a student ambassador program in the U.S. These initiatives aim to enhance community connections and awareness during challenging times. Mary Frances Harmon emphasized the importance of patient advocacy amid the ongoing challenges faced by rare disease patients.
PTC Therapeutics (NASDAQ: PTCT) will present a company overview at the Cantor Virtual Global Healthcare Conference on September 17, 2020, at 9:20 a.m. ET. The presentation will be available via live webcast on the PTC Therapeutics website, with an archive accessible for 30 days post-event. PTC focuses on developing innovative treatments for rare disorders, driving investment through a robust pipeline aimed at addressing unmet medical needs.
PTC Therapeutics announced a significant $20 million milestone payment from Roche triggered by the first commercial sale of Evrysdi™ (risdiplam) in the U.S. The FDA approved Evrysdi™ on August 7, 2020, for treating spinal muscular atrophy (SMA) in individuals 2 months and older. This oral treatment can be administered at home, enhancing patient accessibility during the COVID-19 pandemic. Evrysdi™ aims to improve survival motor neuron protein levels, addressing a critical unmet need in SMA care.
On August 18, 2020, PTC Therapeutics (NASDAQ: PTCT) approved non-statutory stock options for 49,165 shares and 14,175 restricted stock units (RSUs) to five new employees as part of their compensation. The stock options have an exercise price of $49.13 and vest over four years, rewarding 25% after the first year, with additional vesting every three months. The RSUs will vest similarly over four years. These inducement grants comply with NASDAQ Listing Rule 5635(c)(4) and are aimed at enhancing the company's talent acquisition strategy.
PTC Therapeutics (NASDAQ: PTCT) announced the European Medicines Agency's acceptance of its Marketing Authorization Application for Evrysdi™ (risdiplam) to treat spinal muscular atrophy (SMA). This follows the PRIME designation granted by the EMA, facilitating accelerated review. The milestone triggers a $15 million payment from Roche to PTC. Evrysdi™ has shown significant clinical efficacy and safety in trials, including improvements in motor functions. The FDA previously approved the drug for patients aged 2 months and older. This progress aims to broaden access for SMA patients globally.
PTC Therapeutics, Inc. announced FDA approval for Evrysdi™ (risdiplam), the first at-home treatment for spinal muscular atrophy (SMA) in patients aged 2 months and older. Evrysdi demonstrated significant improvements in motor function and survival rates across two pivotal trials, involving over 450 patients. Evrysdi will be launched in the U.S. within two weeks, with Genentech marketing the product. The approval builds on a strong clinical program showcasing its efficacy and safety, making it a notable advancement in SMA treatment.
FAQ
What is the current stock price of Ptc Therapeutics (PTCT)?
What is the market cap of Ptc Therapeutics (PTCT)?
